SELLAS Life Sciences CEO Angelos Stergiou and "Some Future Day" author Marc Beckman predict artificial intelligence will ...

The company on Wednesday announced it paid $47 million up front to license MRG007, a drug developed by Lepu Biopharma, a Shanghai-based developer of cancer therapies. MRG007 is an antibody drug ...

A Bay Area biotech is suing its insurance company to cover costs associated with patients allegedly injured during clinical ...

A temporary freeze on meetings on the National Institutes of Health could lead to delays in disbursing research grants and in ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I’m still recovering from yesterday, when Chicago was ...

Scientists nationwide said the cancellation of NIH grant reviews has thrown early-career scientists into limbo ...

An update from Evaxion Biotech ( ($EVAX) ) is now available. On January 15, 2025, Evaxion Biotech announced the completion of ...

Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...

Biotechnology sits at a fascinating crossroads ... team focused on creating new standards of care for patients with cancer and autoimmune diseases through a modality-agnostic, targeted approach.

Anixa Biosciences CEO Amit Kumar discusses the biotech’s plans for advancing a breast cancer vaccine in 2025. The cancer ...

Biotech startup Exsure has raised Rs 3 crore in a funding round led by Unicorn India Ventures to advance its exosomal drug-delivery platform for anti-cancer treatments. The funds will support Exsure's ...

The UK drugmaker will pay $1 billion upfront for IDRx, whose lead drug for gastrointestinal tumors shows potential against ...